• 3-Deazaadenosine Hydrochloride: Assay Logic

  2026-08-18

  3-Deazaadenosine hydrochloride is an S-adenosylhomocysteine hydrolase inhibitor for interrogating methylation-dependent biology. This guide develops a causal assay framework linking SAHH perturbation to m6A-controlled RNA stability without confusing upstream metabolic effects with direct reader inhibition.

• Bradford Protein Assay Kit: Practical Guide

  2026-08-18

  The Bradford Protein Assay Kit (SKU K4103) provides a rapid biochemical protein assay for measuring protein concentration in solution with a small sample volume. It is best suited to purified proteins and compatible extracts, but samples containing detergents or high concentrations of interfering substances should be evaluated carefully or measured with an alternative method.

• Endothelial SGK1 Drives Vascular Stiffening

  2026-08-17

  Zhang and colleagues identify endothelial SGK1 as a causal mediator of salt-sensitive endothelial and aortic stiffening, linking mineralocorticoid and sodium signaling to actin remodeling. Their combination of global and endothelial-specific genetics with human endothelial-cell pharmacology supports SGK1 as a mechanistic target for hypertension research while clarifying the limits of extrapolation to clinical treatment.

• Caspase-3 Activity: From Mechanism to Translation

  2026-08-17

  Caspase-3 activity is more than an apoptosis endpoint: it can connect upstream stress signaling with execution-phase biology and translational decision-making. This article examines how a fluorometric DEVD-AFC assay can help validate the hyperthermia–cisplatin mechanism described in a 2024 cancer study while clarifying assay scope, controls, and strategic use.

• Biotin-tyramide: From Signal Gain to Translation

  2026-08-16

  A mechanistic and strategic guide to using Biotin-tyramide for spatially resolved detection, informed by a recent tyramide signal amplification study of a structure-switching botulinum neurotoxin aptamer.

• Cell Death in Liver Disease: Mechanisms and Relevance

  2026-08-15

  The reference review presents hepatocyte death as both a biomarker of liver injury and a mechanistic driver of inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Its central innovation is to distinguish apoptosis, necrosis, and necroptosis by the downstream cell death responses they elicit, providing a framework for interpreting biomarkers and evaluating pathway-directed interventions.

• CHK1 Inhibition in Breast Cancer: ER/PR-Dependent Effects

  2026-08-14

  This study shows that CHK1 inhibition cannot be applied uniformly across breast cancer subtypes: it enhances adriamycin sensitivity in ER−/PR−/HER2− disease but acts mainly as a single-agent strategy in ER+/PR+/HER2− cells. By integrating receptor stratification, functional assays, and transcriptome analysis, the work links these divergent responses to distinct checkpoint, mitotic, and apoptotic mechanisms.

• Imatinib (STI571) in Hypoxia-Linked Kinase Research

  2026-08-14

  Imatinib (STI571) offers a precise way to interrogate Abl, PDGF receptor, and c-Kit signaling in erythroleukemia models. This article translates recent HIF/GATA1 findings into a context-aware assay strategy for cancer biology research and kinase pathway interpretation.

• 3-Deazaadenosine Hydrochloride in Fibrosis

  2026-08-13

  A mechanistic and translational guide to using 3-Deazaadenosine hydrochloride as an S-adenosylhomocysteine hydrolase inhibitor for methylation, hepatic stellate cell, inflammation, and fibrosis research.

• RSL3–PARP1 Crosstalk in Ferroptosis and Apoptosis

  2026-08-13

  The reference study shows that RSL3 connects ferroptosis to apoptosis through two coordinated PARP1-regulatory mechanisms: caspase-dependent cleavage and depletion of full-length PARP1 through altered METTL3-mediated m6A regulation. These findings clarify how an established ferroptosis inducer can retain pro-apoptotic activity in PARP inhibitor-resistant cancer models and provide a framework for combining cell-death pathway analysis with direct caspase activity measurement.

• Moxifloxacin Workflows for Toxicity and Gyrase Research

  2026-08-12

  Moxifloxacin supports a connected research workflow spanning bacterial DNA gyrase assays, retinal ganglion cell viability studies, and systemic toxicity models. This guide emphasizes concentration control, mechanism-aware readouts, and troubleshooting strategies that help distinguish antibacterial activity from mammalian or metabolic stress.

• EMD638683: SGK1 Inhibitor Evidence and Workflows

  2026-08-12

  EMD638683 is a selective SGK1 inhibitor for mechanistic studies of sodium-channel signaling, endothelial stiffness, NDRG1 phosphorylation, and tumor-cell responses. Biochemical, cellular, animal, and vascular-model evidence supports research use, while assay-dependent potency and limited translational evidence define its boundaries.

• H-89: A Causal Map for PKA Signaling Assays

  2026-08-11

  H-89 is a cAMP-dependent protein kinase inhibitor that can help separate PKA-dependent signaling from downstream metabolic and phenotypic effects. This article develops a time-aware assay strategy connecting H-89 use with Wnt-driven O-GlcNAcylation, glycolysis, and osteoblast function.

• p-tau Ser356 and NUAK Inhibition in Alzheimer’s

  2026-08-11

  Taylor et al. characterize tau phosphorylated at Ser356 as a pathology-associated species that increases with Alzheimer’s disease progression, appears in neurofibrillary tangles, and localizes near synapses. Their ex vivo experiments show that WZ4003 lowers p-tau Ser356 in human brain slices, while mouse slices display broader, culture-dependent reductions in tau and neuronal proteins, highlighting important model-specific constraints.

• CBD and Endocannabinoid Mechanisms in Orofacial Pain

  2026-08-10

  This 2026 reference study shows that cannabidiol reduces both sensory pain and pain-associated affective and cognitive deficits in mouse inflammatory pain models. Its main contribution is a multilevel mechanistic framework linking peripheral CB2 signaling, central CB1 pathways, inflammatory and oxidative control, and serotonin dynamics in the central amygdala.

15882 records 1/1059 page Next 12345 下5页 Last page